Table 1

Characteristics of patients with pSS included in the ASSESS cohort

CharacteristicsPNS involvementCNS involvementNo NS involvementNS involvementTotalp Value*
Age, years62 (+/−11)61 (+/−11)57 (+/−12)61 (+/−11)58 (+/−12)0.007
Female gender56/63 (89%)3/14 (21%)302/318 (95%)65/74 (88%)367/392 (94%)0.024
Age at diagnosis, years54 (+/−11)53 (+/−8)51 (+/−13)54 (+/−11)51 (+/−12)0.075
Age at symptom onset, years48 (+/−12)50 (+/−8)46 (+/−14)48 (+/−12)46 (+/−13)0.336
Corticosteroids50/63 (79%)9/14 (64%)158/318 (50%)57/74 (77%)215/392 (55%)<0.001
Hydroxychloroquine43/63 (68%)5/14 (36%)173/318 (54%)47/74 (63%)220/392 (56%)0155
IMD/ISD18/63 (29%)7/14 (50%)44/318 (14%)24/74 (32%)68/392 (17%)<0.001
IVIg5/63 (8%)0/14 (0%)4/318 (1%)5/74 (7%)9/392 (2%)0.004
Rituximab8/63 (13%)1/14 (7%)12/317 (4%)9/74 (12%)21/391 (5%)0.004
ESSDAI9.9 (+/−6.8)8.1 (+/−6.2)4.3 (+/−4.8)9.4 (+/−6.8)4.8 (+/−5.5)<0.001
Vasculitis17/62 (27%)4/14 (29%)30/318 (9%)21/73 (29%)51/391 (13%)<0.001
Cryoglobulinemia12/53 (23%)2/14 (14%)44/272 (16%)13/64 (20%)57/336 (17%)0.460
Monoclonal component10/49 (20%)0/10 (0%)34/257 (13%)10/58 (17%)44/315 (14%)0.426
Anti-SSA antibodies30/63 (48%)6/14 (43%)194/318 (61%)34/74 (46%)228/392 (58%)0.012
Anti-SSB antibodies14/63 (22%)2/14 (14%)113/318 (35%)16/74 (22%)129/392 (33%)0.018
  • *Comparison of patients with and without NS involvement.

  • Anti-SSA, anti-Sjögren's syndrome A antibodies; Anti-SSB, anti-Sjögren's syndrome B antibodies; CNS, central nervous system; IMD/ISD, immunomodulating/immunosuppressive drugs, that is, mycophenolate mofetil, methotrexate, leflunomide, azathioprine and cyclophosphamide; IVIg, intravenous immunoglobulins; NS, nervous system; PNS, peripheral nervous system.